You almost want to say that Pfizer
When the drug giant licensed Protalix BioTherapeutics'
At least Pfizer was smart enough to hedge its bet by only paying $60 million up front and tying the other $55 million to regulatory milestones.
Protalix uses a plant-cell system to produce the drugs instead of the mammalian cells used to produce most biotech drugs. Examples of the latter include Amgen's
The clear beneficiary of the delay is Genzyme
Shire
It's almost a given that Pfizer and Protalix will eventually gain FDA approval because, unlike efficacy or safety issues, manufacturing issues can usually be fixed. The only questions are how long it'll take and at what cost.